keyword
MENU ▼
Read by QxMD icon Read
search

Rifaximin

keyword
https://www.readbyqxmd.com/read/28215517/rifaximin-and-diverticular-disease-position-paper-of-the-italian-society-of-gastroenterology-sige
#1
Rosario Cuomo, Giovanni Barbara, Bruno Annibale
Management of diverticular disease has significantly improved in the last decade. Antibiotic treatment is used for symptom relief and prevention of complications. In Italy, the non-absorbable antibiotic rifaximin is one of the most frequently used drugs, and it is perceived as the reference drug to treat symptomatic diverticular disease. Its non-systemic absorption and high faecal concentrations have oriented rifaximin use to the gastrointestinal tract, where rifaximin exerts eubiotic effects representing an additional value to its antibiotic activity...
February 1, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28204967/advantageous-solubility-permeability-interplay-when-using-amorphous-solid-dispersion-asd-formulation-for-the-bcs-class-iv-p-gp-substrate-rifaximin-simultaneous-increase-of-both-the-solubility-and-the-permeability
#2
Avital Beig, Noa Fine-Shamir, David Lindley, Jonathan M Miller, Arik Dahan
Rifaximin is a BCS class IV (low-solubility, low-permeability) drug and also a P-gp substrate. The aims of this work were to assess the efficiency of different rifaximin amorphous solid dispersion (ASDs) formulations in achieving and maintaining supersaturation and to investigate the consequent solubility-permeability interplay. Spray-dried rifaximin ASDs were prepared with different hydrophilic polymers and their ability to achieve and maintain supersaturation was assessed. Then, rifaximin's apparent intestinal permeability was investigated as a function of increasing supersaturation both in vitro using the parallel artificial membrane permeability assay (PAMPA) and in vivo using the single-pass rat intestinal perfusion (SPIP) model...
February 15, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28203283/current-and-emergent-pharmacologic-treatments-for-irritable-bowel-syndrome-with-diarrhea-evidence-based-treatment-in-practice
#3
REVIEW
Susan Lucak, Lin Chang, Albena Halpert, Lucinda A Harris
Irritable bowel syndrome with diarrhea (IBS-D) is a common, chronic functional gastrointestinal disorder with symptoms that can be distressing for patients and often result in substantially impaired quality of life. This review focuses on providing clinicians with information on practical, evidence-based treatment for IBS-D. Current therapies commonly used for the treatment of IBS-D, including pharmacologic and nonpharmacologic interventions, are briefly reviewed, followed by discussion of the emergent pharmacologic treatments (rifaximin and eluxadoline) and medical foods (IBgard(®) and EnteraGam(®))...
February 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28177545/retrospective-cross-sectional-pilot-study-of-rifaximin-dosing-for-the-prevention-of-recurrent-hepatic-encephalopathy
#4
REVIEW
Kelsey C Lyon, Eric Likar, Jay L Martello, Michael Regier
Standard treatment for hepatic encephalopathy (HE) includes medications that reduce ammonia and bacterial translocation in the gut. Rifaximin can be used off-label for the reduction of overt HE. The study purpose was to determine efficacy of traditional rifaximin dosing (400 mg three times daily) compared to newer dosing (550 mg twice daily) via readmission rates for the prevention of recurrent HE. This was a retrospective, observational, cross-sectional pilot study conducted in a tertiary medical center...
February 8, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28172428/p104-rebamipide-sucralfate-and-rifaximin-have-the-suppressive-effects-on-radiation-induced-inflammation-in-the-intestine-of-mouse
#5
W Moon, S J Park, J H Kim, M I Park, S E Kim, K W Jung
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28164845/small-intestinal-bacterial-overgrowth-and-other-intestinal-disorders
#6
REVIEW
Uday C Ghoshal, Ujjala Ghoshal
Gut microbiota is the largest organ of the human body. Although growth of bacteria more than 10(5) colony forming unit (CFU) per milliliter in culture of upper gut aspirate is used to diagnosis small intestinal bacterial overgrowth (SIBO), 10(3) CFU or more is being considered to suggest the diagnosis, particularly if colonic type bacteria are present in the upper gut. Although neither very sensitive nor specific, hydrogen breath tests are widely used to diagnose SIBO. Rifaximin is the best treatment for SIBO due to its broad spectrum, lack of systemic absorption, and safety profile...
March 2017: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/28161290/safety-of-treatments-for-inflammatory-bowel-disease-clinical-practice-guidelines-of-the-italian-group-for-the-study-of-inflammatory-bowel-disease-ig-ibd
#7
Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, Renata D'Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Monica Milla, Ambrogio Orlando, Claudio Papi, Carmelina Petruzziello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci
Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs...
January 17, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28134620/rifaximin-in-treatment-of-patients-with-irritable-bowel-syndrome
#8
Bhupinder Romana, Veysel Tahan
No abstract text is available yet for this article.
January 2017: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/28129384/blood-trimethylamine-n-oxide-originates-from-microbiota-mediated-breakdown-of-phosphatidylcholine-and-absorption-from-small-intestine
#9
Wolfgang Stremmel, Kathrin V Schmidt, Vera Schuhmann, Frank Kratzer, Sven F Garbade, Claus-Dieter Langhans, Gert Fricker, Jürgen G Okun
Elevated serum trimethylamine-N-oxide (TMAO) was previously reported to be associated with an elevated risk for cardiovascular events. TMAO originates from the microbiota-dependent breakdown of food-derived phosphatidylcholine (PC) to trimethylamine (TMA), which is oxidized by hepatic flavin-containing monooxygenases to TMAO. Our aim was to investigate the predominant site of absorption of the bacterial PC-breakdown product TMA. A healthy human proband was exposed to 6.9 g native phosphatidylcholine, either without concomitant treatment or during application with the topical antibiotic rifaximin, or exposed only to 6...
2017: PloS One
https://www.readbyqxmd.com/read/28112426/randomised-clinical-trial-rifaximin-versus-placebo-for-the-treatment-of-functional-dyspepsia
#10
V P Y Tan, K S H Liu, F Y F Lam, I F N Hung, M F Yuen, W K Leung
BACKGROUND: Gut dysbiosis may contribute to pain and bloating in patients with functional gastrointestinal disease. AIMS: To determine if treatment with rifaximin would improve the symptoms of functional dyspepsia in Chinese patients in a double-blinded, randomised, placebo-controlled trial. METHODS: Consecutive subjects with a diagnosis of functional dyspepsia as per the Rome III criteria were randomised to receive rifaximin 400 mg or placebo, all taken three times daily for 2 weeks...
March 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28078798/systematic-review-with-meta-analysis-rifaximin-is-effective-and-safe-for-the-treatment-of-small-intestine-bacterial-overgrowth
#11
REVIEW
L Gatta, C Scarpignato
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome, characterised by an increased number and/or abnormal type of bacteria in the small bowel. Over the past decades, rifaximin has gained popularity for this indication despite its use is not evidence based. AIM: To perform a systematic review and meta-analysis to summarise evidence about the efficacy and safety of rifaximin to eradicate SIBO in adult patients. METHODS: MEDLINE, EMBASE, CCRCT, Scopus and Web of Science were searched from inception to March 16, 2015 for RCTs and observational studies...
March 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28070176/advances-in-ibs-2016-a-review-of-current-and-emerging-data
#12
Philip S Schoenfeld
Irritable bowel syndrome (IBS) is characterized by chronic intermittent abdominal pain and associated diarrhea (IBS-D), constipation (IBS-C), or both. IBS can significantly impact patient function and quality of life. The diagnosis of IBS is based on the presence of characteristic symptoms, the exclusion of concerning features, and selected tests to exclude organic diseases that can mimic IBS. The pathophysiology of IBS remains incompletely understood, and new contributing factors have been identified over the past decade...
August 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28059938/the-effects-of-probiotics-and-symbiotics-on-risk-factors-for-hepatic-encephalopathy-a-systematic-review
#13
Daniela Viramontes Hörner, Amanda Avery, Ruth Stow
Alterations in the levels of intestinal microbiota, endotoxemia, and inflammation are novel areas of interest in the pathogenesis of hepatic encephalopathy (HE). Probiotics and symbiotics are a promising treatment option for HE due to possible beneficial effects in modulating gut microflora and might be better tolerated and more cost-effective than the traditional treatment with lactulose, rifaximin or L-ornithine-L-aspartate. A systematic search of the electronic databases PubMed, ISI Web of Science, EMBASE, and Cochrane Library was conducted for randomized controlled clinical trials in adult patients with cirrhosis, evaluating the effect of probiotics and symbiotics in changes on intestinal microflora, reduction of endotoxemia, inflammation, and ammonia, reversal of minimal hepatic encephalopathy (MHE), prevention of overt hepatic encephalopathy (OHE), and improvement of quality of life...
January 5, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28051800/%C3%A2-minimal-hepatic-encephalopathy-in-cirrhosis-how-long-to-treat
#14
Omesh Goyal, Sandeep S Sidhu, Harsh Kishore
INTRODUCTION: Minimal hepatic encephalopathy (MHE) can reverse after short-term treatment. However, relapse rate of MHE after stopping treatment has not been studied so far. We aimed to evaluate long-term (9 months) efficacy of a short-term (3 months) treatment of MHE with lactulose/rifaximin, for maintenance of remission from MHE. MATERIAL AND METHODS: In this prospective study, consecutive patients with cirrhosis and MHE were treated with lactulose/rifaximin for 3 months...
January 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28034350/rifaximin-chitosan-nanoparticles-for-inflammatory-bowel-disease-ibd
#15
Maria John Newton, Jatinder Kumar
BACKGROUND: Inflammatory Bowel Disease ( IBD) can't be controlled easily and the recurrence is most challenging issue for the physicians. There are various controlled and colon targeted drug delivery sytems are available for the treatment with limited success rate. Nanoparticles prepared by using the colon targeted polymers such as chitosan may improve the IBD due to their smaler size, unique physico chemical properties and targeting potential. OBJECTIVE: The aim of this investigation was designed to formulate and develop a colon targeted polysaccharide nanoparticles of Rifaximin (RFX) by using linear polysaccharide chitosan, for the improvement of rifaximin solubility, overall therapeutic efficacy and colon targeting...
December 30, 2016: Recent Patents on Inflammation & Allergy Drug Discovery
https://www.readbyqxmd.com/read/28007576/rifaximin-reduces-number-and-severity-of-intestinal-lesions-associated-with-use-of-non-steroidal-anti-inflammatory-drugs-in-humans
#16
Carmelo Scarpignato, Werner Dolak, Angel Lanas, Peter Matzneller, Cecilia Renzulli, Maria Grimaldi, Markus Zeitlinger, Ingvar Bjarnason
The intestinal microbiota might contribute to enteropathy associated with use of non-steroidal anti-inflammatory drugs (NSAIDs), but there have been few human studies of this association. We performed a placebo-controlled study to determine whether a delayed release antibiotic formulation (rifaximin-EIR) prevented development of intestinal lesions in persons taking daily NSAIDs. Sixty healthy volunteers (median age 26 years, 42% female) were given the NSAID diclofenac (75 mg twice daily) plus omeprazole (20 mg once daily), and either rifaximin-EIR (400 mg) or placebo, twice daily for 14 days...
December 19, 2016: Gastroenterology
https://www.readbyqxmd.com/read/27981532/rifaximin-modulates-5-fluorouracil-induced-gastrointestinal-mucositis-in-rats
#17
L Ciobanu, M Tantau, S Valean, A Parau, I Bedecean, R Mîrleneanu, C Berce, C Catoi, M Taulescu
OBJECTIVE: This study assessed the protective potential of rifaximin in 5-fluorouracil (5-FU) induced intestinal mucositis in the Wistar rats'. MATERIALS AND METHODS: Twenty-nine Wistar rats were divided into 4 interventional groups of 6 animals (A, B, C and F) and one control group (M) of 5 animals. Groups A, B and C received for three days consecutively rifaximin orally: 50 mg/kg (group A), 100 mg/kg (group B) and 200 mg/kg (group C). In the fourth day, 500 mg/kg of 5-FU was administered intraperitoneally to the groups A, B, C and F...
December 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27977438/improvement-of-sleep-architecture-parameters-in-cirrhotic-patients-with-recurrent-hepatic-encephalopathy-with-the-use-of-rifaximin
#18
Marie Bruyneel, Thomas Sersté, Walter Libert, Sandra van den Broecke, Lieveke Ameye, Bernard Dachy, Jean-Pierre Mulkay, Christophe Moreno, Thierry Gustot
BACKGROUND AND AIM: Sleep disorders are frequently reported in patients with cirrhosis and hepatic encephalopathy (HE). This study assessed the effect of rifaximin on sleep architecture parameters in patients with recurrent HE. PATIENTS AND METHODS: This sequential, prospective, and exploratory study involved all patients with cirrhosis and recurrent HE admitted between June 2014 and September 2015. HE was assessed according to the West-Haven Classification. Patients underwent 24-h polysomnography (PSG) and 7-day actigraphy...
March 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27973463/rationale-and-evidences-for-treatment-of-symptomatic-uncomplicated-diverticular-disease
#19
Rosario Cuomo, Martina Cargiolli, Paolo Andreozzi, Francesco P Zito, Giovanni Sarnelli
INTRODUCTION: Symptomatic uncomplicated diverticular disease (SUDD) is one of the possible clinical manifestations of diverticular disease. It is a common disorder characterized by chronic abdominal symptoms ranging from lower left abdominal pain to alteration of bowel habit, that significantly reduce quality of life of subject affected. The present article aims to review the current data for medical management of SUDD. EVIDENCE ACQUISITION: We analyzed the existing literature on the factors involved in the pathogenesis of SUDD and we highlighted the possible target for treatment...
December 14, 2016: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/27971326/cost-effectiveness-analysis-of-rifaximin-%C3%A3-administration-for-the-reduction-of-the-overt-hepatic-encephalopathy-episodes-in-recurrence-in-france
#20
A Kabeshova, R Launois
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
17795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"